CD4 and mesothelioma: While both CD26high and Th17 cells engineered to express mesothelin-specific CARs were therapeutic in murine models of mesothelioma, human CD26high T cells mediated more durable immune responses and persisted relative to the other CD4 + T cell subsets (Th1, Th2, and Th17), with bulk CD4 or Th17 cell therapies producing only transient delays in tumor growth [92].